Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma.
about
Medical management of lung cancer: Experience in ChinaWill the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?Personalized treatment strategies for non-small-cell lung cancer in Chinese patients: the role of crizotinibCT-guided aspiration lung biopsy for EGFR and ALK gene mutation analysis of lung cancer.ALK-rearrangements and testing methods in non-small cell lung cancer: a reviewClinical characteristics and outcomes of patients with primary lung adenocarcinoma harboring ALK rearrangements detected by FISH, IHC, and RT-PCR.Screening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements.Platform comparison for evaluation of ALK protein immunohistochemical expression, genomic copy number and hotspot mutation status in neuroblastomasAccurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistryAccurate and economical detection of ALK positive lung adenocarcinoma with semiquantitative immunohistochemical screeningDetection of ROS1 gene rearrangement in lung adenocarcinoma: comparison of IHC, FISH and real-time RT-PCRIdentification of five driver gene mutations in patients with treatment-naïve lung adenocarcinoma in TaiwanOverview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement.Anaplastic Lymphoma Kinase Rearrangement in Digestive Tract Cancer: Implication for Targeted Therapy in Chinese Population.Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancerDetection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screeningCrizotinib versus platinum-based double-agent chemotherapy as the first line treatment in advanced anaplastic lymphoma kinase-positive lung adenocarcinoma.Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.High concordance of ALK rearrangement between primary tumor and paired metastatic lymph node in patients with lung adenocarcinoma.Sensitive and affordable diagnostic assay for the quantitative detection of anaplastic lymphoma kinase (ALK) alterations in patients with non-small cell lung cancer.Detection of ALK translocation in non-small cell lung carcinoma (NSCLC) and its clinicopathological significance using the Ventana immunohistochemical staining method: a single-center large-scale investigation of 1, 504 Chinese Han patients.Combination of conventional immunohistochemistry and qRT-PCR to detect ALK rearrangement.ALK gene expression status in pleural effusion predicts tumor responsiveness to crizotinib in Chinese patients with lung adenocarcinomaDevelopment of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer.Guideline Recommendations for Testing of ALK Gene Rearrangement in Lung Cancer: A Proposal of the Korean Cardiopulmonary Pathology Study Group.Comparison of small biopsy specimens and surgical specimens for the detection of EGFR mutations and EML4-ALK in non-small-cell lung cancer.Efficacy of D5F3 IHC for detecting ALK gene rearrangement in NSCLC patients: a systematic review and meta-analysis.A retrospective study of urokinase-type plasminogen activator receptor (uPAR) as a prognostic factor in cancer of the uterine cervix.An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators.Ventana immunohistochemistry assay for anaplastic lymphoma kinase gene rearrangement detection in patients with non-small cell lung cancer: A meta-analysis.ALK expression is absent in pancreatic ductal adenocarcinoma.Performance of a RT-PCR Assay in Comparison to FISH and Immunohistochemistry for the Detection of ALK in Non-Small Cell Lung Cancer.Anaplastic Lymphoma Kinase (ALK) Signaling in Lung Cancer.Emerging treatment for ALK-positive lung cancer.Efficacy of crizotinib in first-line treatment of adults with ALK-positive advanced NSCLC.Mitofusin-2 over-expresses and leads to dysregulation of cell cycle and cell invasion in lung adenocarcinoma.Expression level of CRKL and AXL combined with exon 19 deletion in EGFR and ALK status confer differential prognosis of lung adenocarcinoma subtypes.Kinase gene fusions in defined subsets of melanoma.ALK in Non-Small Cell Lung Cancer (NSCLC) Pathobiology, Epidemiology, Detection from Tumor Tissue and Algorithm Diagnosis in a Daily Practice.Homogeneity and High Concordance of ALK Translocation in Primary Lung Adenocarcinoma and Paired Lymph Node Metastasis.
P2860
Q26798257-D8165EE4-8569-408D-9237-CD971BE20516Q27023383-384FF409-B6DA-4F97-9798-6153EB72F6B7Q28083711-459BC22D-6F4C-41F4-B6E8-EC5D42E73A2EQ33684384-D4BF4139-D468-4552-AE42-F44EC31B7D03Q33776835-C86C7F12-B67F-4756-BB61-E8EF267C676FQ33844713-0140A793-0BAC-4B03-9FA9-17693ABCC15DQ33945982-40F2F10A-2A7E-4E88-A5CF-E09F54C4E04CQ34134105-6C50B1BD-BAEA-4129-A632-47BAE92C7DC8Q34231928-BAC676B9-457D-4CEF-8330-DC2332C42D50Q35131017-370842C8-C778-4C31-9D14-3CD534E8D67EQ35151926-934118D7-D3E8-49D3-BA8C-03B3AFE14BD6Q35196603-8BF84127-6847-492E-9E51-B7F33AD549E3Q35256603-16060832-2369-4657-A4F9-E39C93DFB9F5Q35871758-325B4987-3880-4FF2-A8AE-1466A72FBA78Q36096398-E8D664A9-C928-4F74-9CCB-7BC4EBD00675Q36414458-2BDB785B-5601-49E7-A1A3-4D6ECC590EC9Q36477735-3B4D0331-5122-4963-A3CA-9FDA48B6FF00Q36946796-093B3B06-591E-47CE-9A32-076C1CA18AE3Q36948934-EF9B6D1B-ED33-470C-B1E7-A3F42B881707Q37392933-210D042A-A56E-452E-BA3D-2524F973A204Q37402096-9D3F50A9-273F-4E23-ADF8-BB3B7BA146EDQ37583862-4AA19952-2F3D-4909-80BD-CB79BCA413F4Q37592223-37819D65-DC33-4792-84F8-BCE97B5B9818Q37630493-7B824158-4D8C-493A-8074-066C855C0842Q37631021-16AAAFE6-C0B9-4C1A-83F1-8B091BDA9725Q37644815-1E679FB3-FB67-4A07-B46C-CF8BA7865D5BQ37688499-C2E253A2-E4F0-4D97-8A62-73823E4221F3Q38182915-517127D0-07D0-40FA-A95A-899438E3DA10Q38203761-05CF1318-1E3A-4A5A-8112-F9AE4688491AQ38369482-891B6B6E-47BA-4485-B95F-CCE06773B26AQ38390927-3B923B6E-2103-4C8D-91FE-F781DA6D1BD5Q38649524-AC3EE02A-8F31-448A-A8D0-76FE6EB76791Q38669285-CA137182-BA56-45E1-AE1A-4F88417196E7Q38819472-43648C11-FF89-4A40-828B-EBC1A23AB4A1Q38846823-FA524AA5-43D3-4737-912F-2A93E275C66FQ39026689-7D196906-A589-4CBF-83AC-8AE1BB2A1C17Q39144184-38F38A4B-7BAF-4CC6-9E75-ECE50AD43917Q39172703-B8C304F8-7753-4C29-A0A1-83758FD01287Q40084048-D127152E-AF99-4B04-A101-8D9058C064A3Q41475904-396749E6-E5D6-4F6C-B3CB-2B086E7B7668
P2860
Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Diagnostic value of a novel fu ...... n primary lung adenocarcinoma.
@en
Diagnostic value of a novel fu ...... n primary lung adenocarcinoma.
@nl
type
label
Diagnostic value of a novel fu ...... n primary lung adenocarcinoma.
@en
Diagnostic value of a novel fu ...... n primary lung adenocarcinoma.
@nl
prefLabel
Diagnostic value of a novel fu ...... n primary lung adenocarcinoma.
@en
Diagnostic value of a novel fu ...... n primary lung adenocarcinoma.
@nl
P2093
P2860
P921
P356
P1433
P1476
Diagnostic value of a novel fu ...... n primary lung adenocarcinoma.
@en
P2093
P2860
P304
P356
10.1093/ANNONC/MDT295
P577
2013-07-31T00:00:00Z